Polypill eligibility and equivalent intake in a Swiss population-based study

Abstract The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the population who could benefit from the polypill in Switzerland is unknown. Assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julien Castioni, Nazanin Abolhassani, Peter Vollenweider, Gérard Waeber, Pedro Marques-Vidal
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/71dbf9080ab34f198653c5279a12ddc6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:71dbf9080ab34f198653c5279a12ddc6
record_format	dspace
spelling	oai:doaj.org-article:71dbf9080ab34f198653c5279a12ddc62021-12-02T11:45:02ZPolypill eligibility and equivalent intake in a Swiss population-based study10.1038/s41598-021-84455-82045-2322https://doaj.org/article/71dbf9080ab34f198653c5279a12ddc62021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84455-8https://doaj.org/toc/2045-2322Abstract The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the population who could benefit from the polypill in Switzerland is unknown. Assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2) the determinants of polypill intake in the first (2009–2012) and second follow-ups (2014–2017) of a population-based prospective study conducted in Lausanne, Switzerland. The first and the second follow-ups included 5038 and 4596 participants aged 40–80 years, respectively. Polypill eligibility was defined as having a high CVD risk as assessed by an absolute CVD risk ≥ 5% with the SCORE equation for Switzerland and/or presenting with CVD. Four polypill equivalents were defined: statin + any antihypertensive with (A) or without (B) aspirin; statin + calcium channel blocker (CCB) (C); and statin + CCB + angiotensin-converting enzyme inhibitor (D). The prevalence of polypill eligibility was 20.6% (95% CI 19.5–21.8) and 27.7% (26.5–29.1) in the first and second follow-up, respectively. However, only around one-third of the eligible 29.5% (95% CI 26.7–32.3) and 30.4% (27.9–33.0) respectively, already took the polypill equivalents. All polypill equivalents were more prevalent among men, elderly and in presence of CVD. After multivariable adjustment, in both periods, male gender was associated with taking polypill equivalent A (OR: 1.93; 95% CI 1.45–2.55 and OR: 1.67; 95% CI 1.27–2.19, respectively) and polypill equivalent B (OR: 1.52; 95% CI 1.17–1.96 and OR: 1.41; 95% CI 1.07–1.85, respectively). Similarly, in both periods, age over 70 years, compared to middle-age, was associated with taking polypill equivalent A (OR: 11.71; CI 6.74–20.33 and OR: 9.56; CI 4.13–22.13, respectively) and equivalent B (OR: 13.22; CI 7.27–24.07 and OR: 20.63; CI 6.51–56.36, respectively). Former or current smoking was also associated with a higher likelihood of taking polypill equivalent A in both periods. A large fraction of the population is eligible for the polypill, but only one-third of them actually benefits from an equivalent, and this proportion did not change over time.Julien CastioniNazanin AbolhassaniPeter VollenweiderGérard WaeberPedro Marques-VidalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Julien Castioni Nazanin Abolhassani Peter Vollenweider Gérard Waeber Pedro Marques-Vidal Polypill eligibility and equivalent intake in a Swiss population-based study
description	Abstract The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the population who could benefit from the polypill in Switzerland is unknown. Assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2) the determinants of polypill intake in the first (2009–2012) and second follow-ups (2014–2017) of a population-based prospective study conducted in Lausanne, Switzerland. The first and the second follow-ups included 5038 and 4596 participants aged 40–80 years, respectively. Polypill eligibility was defined as having a high CVD risk as assessed by an absolute CVD risk ≥ 5% with the SCORE equation for Switzerland and/or presenting with CVD. Four polypill equivalents were defined: statin + any antihypertensive with (A) or without (B) aspirin; statin + calcium channel blocker (CCB) (C); and statin + CCB + angiotensin-converting enzyme inhibitor (D). The prevalence of polypill eligibility was 20.6% (95% CI 19.5–21.8) and 27.7% (26.5–29.1) in the first and second follow-up, respectively. However, only around one-third of the eligible 29.5% (95% CI 26.7–32.3) and 30.4% (27.9–33.0) respectively, already took the polypill equivalents. All polypill equivalents were more prevalent among men, elderly and in presence of CVD. After multivariable adjustment, in both periods, male gender was associated with taking polypill equivalent A (OR: 1.93; 95% CI 1.45–2.55 and OR: 1.67; 95% CI 1.27–2.19, respectively) and polypill equivalent B (OR: 1.52; 95% CI 1.17–1.96 and OR: 1.41; 95% CI 1.07–1.85, respectively). Similarly, in both periods, age over 70 years, compared to middle-age, was associated with taking polypill equivalent A (OR: 11.71; CI 6.74–20.33 and OR: 9.56; CI 4.13–22.13, respectively) and equivalent B (OR: 13.22; CI 7.27–24.07 and OR: 20.63; CI 6.51–56.36, respectively). Former or current smoking was also associated with a higher likelihood of taking polypill equivalent A in both periods. A large fraction of the population is eligible for the polypill, but only one-third of them actually benefits from an equivalent, and this proportion did not change over time.
format	article
author	Julien Castioni Nazanin Abolhassani Peter Vollenweider Gérard Waeber Pedro Marques-Vidal
author_facet	Julien Castioni Nazanin Abolhassani Peter Vollenweider Gérard Waeber Pedro Marques-Vidal
author_sort	Julien Castioni
title	Polypill eligibility and equivalent intake in a Swiss population-based study
title_short	Polypill eligibility and equivalent intake in a Swiss population-based study
title_full	Polypill eligibility and equivalent intake in a Swiss population-based study
title_fullStr	Polypill eligibility and equivalent intake in a Swiss population-based study
title_full_unstemmed	Polypill eligibility and equivalent intake in a Swiss population-based study
title_sort	polypill eligibility and equivalent intake in a swiss population-based study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/71dbf9080ab34f198653c5279a12ddc6
work_keys_str_mv	AT juliencastioni polypilleligibilityandequivalentintakeinaswisspopulationbasedstudy AT nazaninabolhassani polypilleligibilityandequivalentintakeinaswisspopulationbasedstudy AT petervollenweider polypilleligibilityandequivalentintakeinaswisspopulationbasedstudy AT gerardwaeber polypilleligibilityandequivalentintakeinaswisspopulationbasedstudy AT pedromarquesvidal polypilleligibilityandequivalentintakeinaswisspopulationbasedstudy
_version_	1718395287494459392

Polypill eligibility and equivalent intake in a Swiss population-based study

Ejemplares similares